Biohaven

Biohaven Stock-Based Compensation

The Stock-Based Compensation (SBC) of Biohaven (BHVN) as of Oct 24, 2026 is 112.36 M USD. In the previous year, Stock-Based Compensation (SBC) was 71.96 M USD — a change of 56.14% (higher).

Stock-Based Compensation

112.36 MUSD

YoY

56.14%

Last updated:

Stock-Based Compensation (SBC) of Biohaven is 2025 112.36 M USD. Stock-Based Compensation (SBC) of Biohaven was 2024 71.96 M USD. It decreases by 56.14% higher compared to the previous year.

The Biohaven Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
16.93 M USD
Jan 1, 2019
54.97 M USD
Jan 1, 2020
29.50 M USD
Jan 1, 2021
65.64 M USD
Jan 1, 2022
193.56 M USD
Jan 1, 2023
28.79 M USD
Jan 1, 2024
71.96 M USD
Jan 1, 2025
112.36 M USD
The Biohaven Stock-Based Compensation history
YEARStock-Based CompensationYoY
112.36 MUSD+56.14%
71.96 MUSD+149.98%
28.79 MUSD-85.13%
193.56 MUSD+194.88%
65.64 MUSD+122.51%
29.50 MUSD-46.34%
54.97 MUSD+224.80%
16.93 MUSD+27.84%
13.24 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biohaven Stock analysis

What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biohaven stock

Stock-Based Compensation (SBC) of Biohaven is 112.36 M USD in 2025.

Stock-Based Compensation (SBC) of Biohaven changed from 71.96 M USD to 112.36 M USD, representing a 56.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Biohaven since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Biohaven historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biohaven

All Key Metrics — Biohaven